Skip to content

Metabolic & GLP-1 · Reference monograph

GLP-1 receptor agonist derived from exendin-4

Reference compound — not available from Purity Peptides. Shown for research context.

Overview

Exenatide is the synthetic form of exendin-4, a 39-amino-acid peptide discovered in the venom of the Gila monster (Heloderma suspectum). In 1992, endocrinologist John Eng at the Bronx Veterans Affairs Medical Center isolated exendin-4 and found that it shares roughly half its sequence with mammalian GLP-1 while resisting rapid degradation by DPP-4.

That stability made exendin-4 an attractive starting point for drug development, and exenatide became the first incretin peptides.">GLP-1 receptor agonist approved for type 2 diabetes, authorised by the FDA in 2005. An extended-release formulation using biodegradable polymer microspheres followed. Exenatide remains an approved prescription medicine for type 2 diabetes in many regions, though availability of individual products has changed over time. In research, exenatide is a classic tool compound: it is widely used in rodent and cell studies of GLP-1 receptor signalling, and its truncated form exendin(9-39) is a standard receptor antagonist. The molecule has also been studied in neurodegeneration research, including Parkinson's disease trials.

Mechanism studied

  1. Exenatide
  2. GLP-1 receptor
  3. Slowed gastric emptying
  4. Postprandial glucose

Exenatide is a full agonist at the GLP-1 receptor. Glycine at position 2 prevents DPP-4 cleavage, which rapidly inactivates native GLP-1. Receptor activation in beta cells increases cAMP, engaging protein kinase A and Epac2 to amplify glucose-stimulated insulin secretion, so the insulinotropic effect diminishes as glucose falls. Exenatide also suppresses inappropriate glucagon release and markedly slows gastric emptying, a prominent effect of shorter-acting agonists that strongly shapes postprandial glucose curves. Rodent studies show exenatide promotes beta-cell proliferation and survival, although the relevance to adult human islets is debated. Clearance occurs mainly by glomerular filtration.

Research highlights

  • 01Isolated from Gila monster venom by John Eng in 1992; the related exendin-3 was found in Heloderma horridum.
  • 02The first GLP-1 receptor agonist approved for type 2 diabetes, by the FDA in 2005.
  • 03The extended-release microsphere formulation is a reference case in polymer-based sustained peptide release science.
  • 04EXSCEL, a large cardiovascular outcome trial, assessed the extended-release form in a broad type 2 diabetes population.
  • 05Phase 2 Parkinson's disease research generated interest, but a larger phase 3 study did not confirm an effect on disease progression.

Latest published research

4,936 papers on PubMed →

  1. Peptide-functionalized nanoemulsions with exendin-4 as a model ligand

    Holler N et al. · International journal of pharmaceutics: X · 2026 Dec · PMID 42472074

  2. Pancreatic δ cells are resistant to auto- and paracrine inhibition in human type-2 diabetes

    Omar-Hmeadi M et al. · Proceedings of the National Academy of Sciences of the United States of America · 2026 Nov 3 · PMID 42945255

  3. Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding

    Sanchez-Navarro MJ et al. · Physiology & behavior · 2026 Nov 1 · PMID 42603595

  4. Impact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis

    Khan SA et al. · Digestive diseases and sciences · 2026 Nov · PMID 42570075

  5. Effects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis

    Sobral MVS et al. · Schizophrenia research · 2026 Nov · PMID 42497473

  6. Comparative Effects of Pharmacological Treatment on Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials

    Zhang J et al. · Drugs · 2026 Oct 29 · PMID 42955666

  7. Oral Health-Related Adverse Events of GLP-1 Receptor Agonists

    Massarotto FC et al. · JDR clinical and translational research · 2026 Oct 27 · PMID 42935458

  8. Skeletal effects of GLP-1 receptor agonist therapy in adults with overweight or obesity: a systematic review

    Lai CH et al. · Archives of osteoporosis · 2026 Oct 23 · PMID 42920024

Live feed from PubMed (NCBI) for “Exenatide”, updated 2026-10-30. Listing a paper is not an endorsement of its findings.

Registered studies

379 on ClinicalTrials.gov →

From the public ClinicalTrials.gov registry for “Exenatide”, updated 2026-10-30. Shown for research context only; Purity Peptides products are not for human use.

Key references

  1. [1]Manufacturer's prescribing information — FDA / EMA / ANVISA
  2. [2]Buse et al., 2004 — Diabetes Care

FAQ

  • Exenatide is a synthetic copy of exendin-4, a peptide found in the venom of the Gila monster. Researchers screening Heloderma venoms for bioactive peptides discovered that exendin-4 activates the mammalian GLP-1 receptor while resisting enzymatic breakdown.

  • Exendin(9-39) is a truncated form of exendin-4 lacking the first eight amino acids. It binds the GLP-1 receptor without activating it and is widely used as a competitive antagonist to probe endogenous GLP-1 physiology in animal and human research.

  • Native GLP-1 is inactivated within minutes by DPP-4 and rapidly cleared. Exenatide shares about half of GLP-1's sequence but carries a glycine at position 2 and other differences that confer DPP-4 resistance, giving it a substantially longer duration of action in experimental systems.

FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.

Related compounds

WhatsApp